What's Hot

View all perspectives
      A new innovative way of teaching MS ultrasound to students using teledidactic teaching with portable ultrasound devices

      Dr. Antoni Chan

      1 year ago
      A new innovative way of teaching MS ultrasound to students using teledidactic teaching with portable ultrasound devices resulted in a significant increase in knowledge comparable to the conventional course, Schäfer SV, Abst#2079 #ACR23 @RheumNow https://t.co/re0gErx5ke https://t.co/yPbS9Rj0az
      Late breaking at #ACR23:
      extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms

      Another six mont

      David Liew drdavidliew

      1 year ago
      Late breaking at #ACR23: extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3! ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85
      Complements & HCQ? (Prof Petri et al)

      Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole

      sheila

      1 year ago
      Complements & HCQ? (Prof Petri et al) Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole blood levels >50 ng/mL Increasing blood levels of HCQ significantly assocd w/⬆️prob of achieving normal C4 Improving C3,C4; addtl benefit of HCQ? #ACR23 ABST2327 @RheumNow https://t.co/5ucpXq9ngb
      #ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#S

      Md Yuzaiful Md Yusof

      1 year ago
      #ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP
      HCQ discontinuation in SLE? Why?!

      In this retro cohort of 42 pts
      Reasons:
      Retinal toxicity (57%)
      Self-discontinuation

      sheila

      1 year ago
      HCQ discontinuation in SLE? Why?! In this retro cohort of 42 pts Reasons: Retinal toxicity (57%) Self-discontinuation (17%) Factors strongly assoc'd w/ flares 1 yr after discontinuation - mean C3 and +dsDNA at index visit. #ACR23 ABST2343 @RheumNow https://t.co/BCO9N4gSkX
      Im usually super shy on camera but my hair looks great in this video with my friend @RHEUMarampa as we talk about how ou

      Lisa 🐳🗺🧭 rheumarhyme

      1 year ago
      Im usually super shy on camera but my hair looks great in this video with my friend @RHEUMarampa as we talk about how our reviewer went from a personal project to a fellow study resource. #ACR23 #ACRambassador @RheumNow @cerego https://t.co/KHDni7epFK
      Pain experience in #OA may have different contributing factors
      Its a while joint disease!
      What are the future targets i

      Bella Mehta bella_mehta

      1 year ago
      Pain experience in #OA may have different contributing factors Its a while joint disease! What are the future targets in #OA being tested? @RheumNow #ACR23 @Tuhina_Neogi https://t.co/lI06pJrdYR
      GCs on MACE in RA in VA
      A#2430 #ACR23 @RheumNow
      Not just ongoing steroid usage, also prior usage 1 year ago
      5 mg use fo

      Eric Dein

      1 year ago
      GCs on MACE in RA in VA A#2430 #ACR23 @RheumNow Not just ongoing steroid usage, also prior usage 1 year ago 5 mg use for 30 days one year ago - increases MACE events by 3% 5 mg use for 90 days one year ago - increases MACE events by 9%
      Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 y

      Richard Conway

      1 year ago
      Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o
      Even low doses of steroids associated with major adverse cardiovascular events!

      Large VA database - >18k RA pts
      Dose

      Robert B Chao, MD

      1 year ago
      Even low doses of steroids associated with major adverse cardiovascular events! Large VA database - >18k RA pts Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE @RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD
      Mok et al. Romosozumab superior to denosumab in high risk GIO. Superior in improving spine BMD. Not fracture. Fracture i

      Richard Conway

      1 year ago
      Mok et al. Romosozumab superior to denosumab in high risk GIO. Superior in improving spine BMD. Not fracture. Fracture is what matters. Abstr#2429 #ACR23 @RheumNow https://t.co/5ModHOGsED
      A#2429 #ACR23 @RheumNow
      ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk
      Mean prednisolone dose 6.6 mg
      H/o fragility fx i

      Eric Dein

      1 year ago
      A#2429 #ACR23 @RheumNow ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk Mean prednisolone dose 6.6 mg H/o fragility fx in 1/2 pts 12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2) Hip and Femoral neck improved both (1.6% both), not signif diff bw grps AEs: incr injxn site rxn https://t.co/VueuZIjFfM
      Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized!
      Mainstay remains weight

      Bella Mehta bella_mehta

      1 year ago
      Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized! Mainstay remains weight loss and exercise! @RheumNow #ACR23 Rrf memorial lecture @Tuhina_Neogi https://t.co/yXqWIEccq4
      McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independe

      Richard Conway

      1 year ago
      McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT
      Gout mortality
      A#2428 #ACR23 @RheumNow
      1988-1994 (early) v 2007-2016 (late): Has not improved over time
      Independent of s

      Eric Dein

      1 year ago
      Gout mortality A#2428 #ACR23 @RheumNow 1988-1994 (early) v 2007-2016 (late): Has not improved over time Independent of serum uric acid Female gout: increased mortality Black gout pts also increased Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu

      Podcasts

      • ACR24 - IL - 17
      • ACR24 - JAK TYK2
      • ACR24 - LUPUS

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.